LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM
LivaNova PLC LIVN, a renowned medical technology company, has received both FDA 510(k) clearance and CE Mark for its Essenz In-Line Blood Monitor (ILBM). This groundbreaking technology, integrated into the Essenz Perfusion System, promises to redefine perfusionists' capabilities by providing continuous and precise measurements of vital blood parameters throughout cardiopulmonary bypass (CPB) procedures.
By providing real-time, accurate monitoring, eliminating calibration and promoting data-driven decision-making, this latest innovation is set to drive the success of LivaNova's cardiopulmonary business and enhance patient outcomes worldwide.
Continuous Monitoring for Informed Decision-Making
Traditionally, blood gas analyzers provide only snapshot data, leaving healthcare professionals with limited insights into a patient's evolving condition during CPB procedures. LivaNova's Essenz ILBM, however, offers real-time, in-line monitoring of essential blood parameters throughout the entire procedure. This continuous monitoring approach empowers perfusionists with a wealth of data, enabling them to make informed, data-driven decisions tailored to each patient's unique needs.
Precision and Compliance
The Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments (CLIA) guidelines. Unlike other systems that rely on calculated values, ILBM provides measured values for critical parameters such as oxygen saturation, hematocrit, partial pressure of oxygen and temperature. This precision is essential for delivering personalized care and optimizing patient outcomes.
Streamlined Workflow and Goal-Directed Perfusion
One of the standout features of Essenz ILBM is its user-friendly design. It requires no calibration during device setup, saving valuable time, especially in emergency cases. Furthermore, the ILBM seamlessly integrates with the Essenz Patient Monitor, facilitating data-driven decision-making and the implementation of goal-directed perfusion, a therapeutic approach known to reduce the risk of acute kidney injury.
Image Source: Zacks Investment Research
Global Impact and Future Growth
Since its launch in February 2023, Essenz Perfusion System, incorporating ILBM, has already supported over 1,000 patients worldwide. Its availability in multiple countries, including Europe, the United States, Canada, Australia, Japan, and the United Arab Emirates, underscores its global impact and potential for future growth.
Going by a Grand View Research report, the global perfusion systems market is poised for substantial growth in the coming years. In 2022, it was valued at $1.07 billion. Projections indicate a CAGR of 4.7% from 2023 to 2030. Several key factors are driving this growth.
The increasing prevalence of cardiovascular and respiratory diseases, coupled with a growing geriatric population and rising instances of multiple organ failures, are significant contributors to the market's expansion. Additionally, the rise in organ transplantation procedures, aided by initiatives to encourage organ donation, is expected to boost demand for perfusion systems.
Despite a temporary setback due to the COVID-19 pandemic, which led to a decline in organ donations and transplants, the market is recovering as countries focus on healthcare and return to normalcy. Furthermore, the introduction of products is anticipated to propel the perfusion system market to pre-pandemic growth rates.
The increasing incidence of cardiac and respiratory diseases, driven by factors like sedentary lifestyles and dietary habits, is a pivotal factor supporting market growth.
Share Price Performance
Over the past year, shares of LIVN have risen 2.7% compared with a 6.5% rise of the industry.
Zacks Rank and Key Picks
LivaNova currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics HAE, Quanterix QTRX and SiBone SIBN.
Haemonetics’ stock has risen 19.9% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and from $3.96 to $4.07 in 2024 in the past 30 days. It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%. It currently carries a Zacks Rank #2 (Buy).
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%. It currently carries Zacks Rank #2.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
LivaNova PLC (LIVN) : Free Stock Analysis Report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
SiBone (SIBN) : Free Stock Analysis Report
